Serina Therapeutics, Inc. (SER) stock
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.42+0.03 (+2.16%)
Close on Nov 16, 2026Market cap $36.07MP/E –Yield –
Serina Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Serina Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$21.14M. For fiscal 2025 it was -$17.96M. The highest annual figure on record is -$2.48M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.96M | – |
| FY2024 | Dec 31, 2024 | -$17.14M | – |
| FY2023 | Dec 31, 2023 | -$2.48M | – |
| FY2022 | Dec 31, 2022 | -$5.94M | – |
| FY2021 | Dec 31, 2021 | -$7.86M | – |
| FY2020 | Dec 31, 2020 | -$7.82M | – |
| FY2019 | Dec 31, 2019 | -$10.16M | – |
| FY2018 | Dec 31, 2018 | -$8.00M | – |
| FY2017 | Dec 31, 2017 | -$6.29M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.57M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.59M | -3892.6% |
| Q3 FY2024 | Sep 30, 2024 | -$2.96M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.58M | – |
| Q4 FY2023 | Dec 31, 2023 | $121.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$864.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$709.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.24M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.75M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.24M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.41M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.37M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.76M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.62M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.05M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.78M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.16M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.01M | – |
See a number that looks wrong?